Keychun Park, Ph.D. - Publications

Affiliations: 
2008 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Mechanical Engineering

160 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Hong DK, Kho AR, Lee SH, Jeong JH, Kang BS, Kang DH, Park MK, Park KH, Lim MS, Choi BY, Suh SW. Transient Receptor Potential Melastatin 2 (TRPM2) Inhibition by Antioxidant, -Acetyl-l-Cysteine, Reduces Global Cerebral Ischemia-Induced Neuronal Death. International Journal of Molecular Sciences. 21. PMID 32825703 DOI: 10.3390/ijms21176026  0.44
2020 Kim G, Kim J, Cha H, Park WY, Ahn JS, Ahn MJ, Park K, Park YJ, Choi JY, Lee KH, Lee SH, Moon SH. Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. Scientific Reports. 10: 13231. PMID 32764738 DOI: 10.1038/s41598-020-70168-x  0.44
2020 Kim H, Kwon M, Kim B, Jung HA, Sun JM, Lee SH, Park K, Ahn MJ. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. Bmc Cancer. 20: 727. PMID 32758163 DOI: 10.1186/s12885-020-07214-4  0.8
2020 Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Evaluating entrectinib as a treatment option for non-small cell lung cancer. Expert Opinion On Pharmacotherapy. 1-8. PMID 32736487 DOI: 10.1080/14656566.2020.1798932  0.8
2020 Lee J, La Choi Y, Han J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32652216 DOI: 10.1016/j.jtho.2020.06.018  0.8
2020 Park S, Lee MH, Seong M, Kim ST, Kang JH, Cho BC, Lee KH, Cho EK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32634610 DOI: 10.1016/j.annonc.2020.06.017  0.8
2020 Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K, Ahn MJ. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 32599977 DOI: 10.4143/crt.2020.278  0.8
2020 Park S, Shim J, Mortimer PGS, Smith SA, Godin RE, Hollingsworth SJ, Kim HJ, Jung HA, Sun JM, Park WY, Ahn JS, Ahn MJ, Lee SH, Park K. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. Cancer. PMID 32584426 DOI: 10.1002/cncr.33048  0.8
2020 Ahn TK, Kim KT, Joshi HP, Park KH, Kyung JW, Choi UY, Sohn S, Sheen SH, Shin DE, Lee SH, Han IB. Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosis. International Journal of Molecular Sciences. 21. PMID 32560070 DOI: 10.3390/ijms21124274  0.44
2020 Park S, Lee E, Park S, Lee S, Nam SJ, Kim SW, Lee JE, Yu JH, Kim JY, Ahn JS, Im YH, Park WY, Park K, Park YH. Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer. Molecular Cancer Research : McR. PMID 32554602 DOI: 10.1158/1541-7786.MCR-19-1108  0.44
2020 Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study). Lung Cancer (Amsterdam, Netherlands). 146: 112-119. PMID 32526601 DOI: 10.1016/j.lungcan.2020.05.033  0.8
2020 Koh J, Kim Y, Lee KY, Hur JY, Kim MS, Kim B, Cho HJ, Lee YC, Bae YH, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. MDSC subtypes and CD39 expression on CD8 T cells predict the efficacy of anti PD-1 immunotherapy in patients with advanced NSCLC. European Journal of Immunology. PMID 32510574 DOI: 10.1002/eji.202048534  0.8
2020 Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ, Pyo H, Ahn YC, Park K. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 146: 23-29. PMID 32505077 DOI: 10.1016/j.lungcan.2020.05.035  0.8
2020 Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH, Choi S, Choi YL, Joung JG, Park WY, Jung HA, ... ... Park K, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nature Communications. 11: 2285. PMID 32385277 DOI: 10.1038/s41467-020-16164-1  0.8
2020 Lee J, Choi Y, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. European Journal of Cancer (Oxford, England : 1990). 132: 150-158. PMID 32371248 DOI: 10.1016/j.ejca.2020.03.029  0.8
2020 Hur JY, Ku BM, Shim JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With Exon 14 Skipping. In Vivo (Athens, Greece). 34: 1399-1406. PMID 32354937 DOI: 10.21873/invivo.11920  0.8
2020 Ahn MS, Eom YW, Oh JE, Cha SK, Park KS, Son JW, Lee JW, Youn YJ, Ahn SG, Kim JY, Lee SH, Yoon J, Yoo BS. Transient receptor potential channel TRPV4 mediates TGF-β1-induced differentiation of human ventricular fibroblasts. Cardiology Journal. PMID 32329036 DOI: 10.5603/CJ.a2019.0050  0.44
2020 Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32320754 DOI: 10.1016/j.annonc.2020.04.004  0.8
2020 Lim SH, Sun JM, Hong J, Oh D, Ahn YC, Chung MK, Jeong HS, Son YI, Ahn MJ, Baek CH, Park K. Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. The Korean Journal of Internal Medicine. PMID 32241084 DOI: 10.3904/kjim.2019.161  0.8
2020 Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. Cancer. PMID 32154925 DOI: 10.1002/cncr.32809  0.8
2020 Lee SH, Kang D, Ok SH, Kim JY, Bae SI, Hwang Y, Park KE, Kim JW, Sohn JT. Lipofundin MCT/LCT Inhibits Levcromakalim-Induced Vasodilation by Inhibiting Endothelial Nitric Oxide Release. International Journal of Molecular Sciences. 21. PMID 32143531 DOI: 10.3390/ijms21051763  0.44
2020 Lee J, Ku BM, Shim JH, La Choi Y, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. Japanese Journal of Clinical Oncology. PMID 32083304 DOI: 10.1093/jjco/hyaa019  0.8
2020 Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology. 9: 1722023. PMID 32076579 DOI: 10.1080/2162402X.2020.1722023  0.8
2020 Kim CW, Jeong WK, Son GM, Kim IY, Park JW, Jeong SY, Park KJ, Lee SH. Validation of the Korean Version of the Low Anterior Resection Syndrome Score Questionnaire. Annals of Coloproctology. PMID 32054239 DOI: 10.3393/ac.2019.08.01  0.44
2020 Byeon S, Cho JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Medicine. PMID 32027780 DOI: 10.1002/cam4.2868  0.8
2020 Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, ... ... Park K, ... ... Park KS, et al. New approaches to small cell lung cancer therapy : from the laboratory to the clinic. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32018053 DOI: 10.1016/j.jtho.2020.01.016  0.44
2020 Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan DSW, Yang JCH, Wang J, Babu KG, Nakayama Y, Alip A, Chua KLM, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 31: 191-201. PMID 31959336 DOI: 10.1016/j.annonc.2019.10.026  0.32
2020 Shin S, Choi YS, Jung JJ, Im Y, Shin SH, Kang D, Cho JH, Kim HK, Kim J, Zo JI, Shim YM, Park K, Ahn MJ, Ahn YC, Lee G, et al. Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. Respiratory Research. 21: 13. PMID 31924201 DOI: 10.1186/s12931-019-1254-0  0.44
2020 Shin E, Lim DH, Han J, Nam DH, Park K, Ahn MJ, Kang WK, Lee J, Ahn JS, Lee SH, Sun JM, Jung HA, Chung TY. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. Bmc Ophthalmology. 20: 19. PMID 31918686 DOI: 10.1186/s12886-019-1285-9  0.8
2020 Lee T, Cho J, Baek CH, Son YI, Jeong HS, Chung MK, Hong SD, Ahn YC, Oh DR, Noh JM, Park K, Ahn MJ, Kim HJ, Kim YK, Ko YH. Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. Head & Neck. PMID 31903701 DOI: 10.1002/hed.26067  0.44
2019 Shin HT, Kim NKD, Yun JW, Lee B, Kyung S, Lee KW, Ryu D, Kim J, Bae JS, Park D, Choi YL, Lee SH, Ahn MJ, Park K, Park WY. JuLI: accurate detection of DNA fusions in clinical sequencing for precision oncology. The Journal of Molecular Diagnostics : Jmd. PMID 31881333 DOI: 10.1016/j.jmoldx.2019.10.015  0.44
2019 Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Clinical Lung Cancer. PMID 31839532 DOI: 10.1016/j.cllc.2019.11.006  0.8
2019 Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900931. PMID 31825714 DOI: 10.1200/JCO.19.00931  0.8
2019 Park S, Lee SH, Park K. In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 14: e279-e280. PMID 31757381 DOI: 10.1016/j.jtho.2019.10.010  0.44
2019 Kim CJ, Song KH, Choe PG, Park WB, Kim ES, Park KU, Kim NJ, Park KH, Kwak YG, Cheon S, Jang HC, Kim YK, Lee SH, Kiem SM, Lee S, et al. The microbiological characteristics of isolated from patients with native valve infective endocarditis. Virulence. 10: 948-956. PMID 31718473 DOI: 10.1080/21505594.2019.1685631  0.44
2019 Kim HS, Cha H, Kim J, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. European Journal of Cancer (Oxford, England : 1990). 120: 65-74. PMID 31493723 DOI: 10.1016/j.ejca.2019.08.001  0.8
2019 Moon SH, Sun JM, Ahn JS, Park K, Kim BT, Lee KH, Ahn MJ, Choi JY. Predictive and Prognostic Value of F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. Scientific Reports. 9: 12215. PMID 31434972 DOI: 10.1038/s41598-019-48674-4  0.8
2019 Lee K, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 31345011 DOI: 10.4143/crt.2019.186  0.8
2019 Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31195179 DOI: 10.1016/j.jtho.2019.05.033  0.8
2019 Park S, Lee H, Lee B, Lee SH, Sun JM, Park WY, Ahn JS, Ahn MJ, Park K. DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31125737 DOI: 10.1016/j.jtho.2019.05.014  0.8
2019 Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Investigational New Drugs. PMID 31124056 DOI: 10.1007/s10637-019-00795-3  0.8
2019 Park S, Joung JG, Min YW, Nam JY, Ryu D, Oh D, Park WY, Lee SH, Choi Y, Ahn JS, Ahn MJ, Park K, Sun JM. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. Journal For Immunotherapy of Cancer. 7: 128. PMID 31097034 DOI: 10.1186/s40425-019-0609-x  0.8
2019 Cho WK, Oh D, Kim HK, Ahn YC, Noh JM, Shim YM, Zo JI, Choi YS, Sun JM, Lee SH, Ahn MJ, Park K, Nam H. Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 133: 87-92. PMID 30935586 DOI: 10.1016/j.radonc.2019.01.005  0.8
2019 Kim WK, No JS, Lee D, Jung J, Park H, Yi Y, Kim JA, Lee SH, Kim Y, Park S, Cho S, Lee GY, Song DH, Gu SH, Park K, et al. Active Targeted Surveillance to Identify Sites of Emergence of Hantavirus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30891596 DOI: 10.1093/cid/ciz234  0.44
2019 Lee K, Kim Y, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Choi YL, Sun JM. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer (Amsterdam, Netherlands). 130: 87-92. PMID 30885357 DOI: 10.1016/j.lungcan.2019.01.012  0.8
2019 Shin SH, Park HY, Im Y, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee HY, Lee SH. Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease. International Journal of Cancer. PMID 30807641 DOI: 10.1002/ijc.32235  0.8
2019 Kim KH, Cho J, Ku BM, Koh J, Sun JM, Lee SH, Ahn JS, Cheon J, Min YJ, Park SH, Park K, Ahn MJ, Shin EC. The first-week proliferative response of peripheral blood PD-1CD8 T cells predicts the response to anti-PD-1 therapy in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30647082 DOI: 10.1158/1078-0432.CCR-18-1449  0.8
2018 Nam BD, Kim TJ, Park K, Ahn MJ, Choi YL, Chung MJ, Kim TS, Lee KS. Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. Clinical Lung Cancer. PMID 30686681 DOI: 10.1016/j.cllc.2018.12.021  0.44
2018 Lee J, Sun JM, Lee SH, Ahn JS, Park K, Choi Y, Ahn MJ. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. Clinical Lung Cancer. PMID 30683630 DOI: 10.1016/j.cllc.2018.12.020  0.8
2018 Kim JY, Kang K, Kang J, Koo J, Kim DH, Kim BJ, Kim WJ, Kim EG, Kim JG, Kim JM, Kim JT, Kim C, Nah HW, Park KY, Park MS, et al. Executive Summary of Stroke Statistics in Korea 2018: A Report from the Epidemiology Research Council of the Korean Stroke Society. Journal of Stroke. PMID 30558400 DOI: 10.5853/jos.2018.03125  0.44
2018 Kim H, Oh D, Ahn YC, Park K, Ahn MJ, Lee SH, Sun JM, Shim YM, Zo JI, Choi YS, Kim HK, Cho JH. Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. Radiation Oncology (London, England). 13: 245. PMID 30547802 DOI: 10.1186/s13014-018-1196-6  0.8
2018 Moon SH, Sun JM, Ahn JS, Park K, Ahn MJ, Choi JY. Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk Stratification. Clinical Nuclear Medicine. PMID 30516679 DOI: 10.1097/RLU.0000000000002394  0.8
2018 Kim Y, Lee B, Shim JH, Lee SH, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30391576 DOI: 10.1016/j.jtho.2018.10.150  0.8
2018 Park KS, Hong MK, Jeon JW, Kim JH, Jeon JH, Lee JH, Kim TY, Karim AM, Malik SK, Kang LW, Lee SH. The novel metallo-β-lactamase PNGM-1 from a deep-sea sediment metagenome: crystallization and X-ray crystallographic analysis. Acta Crystallographica. Section F, Structural Biology Communications. 74: 644-649. PMID 30279316 DOI: 10.1107/S2053230X18012268  0.44
2018 Lim SW, Park S, Kim Y, Cho JH, Park SE, Lee H, Kim HK, Kim SM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. Lung Cancer (Amsterdam, Netherlands). 124: 293-297. PMID 30268476 DOI: 10.1016/j.lungcan.2018.08.003  0.8
2018 Lee KH, Ahn YC, Pyo H, Noh JM, Park SG, Kim TG, Lee E, Nam H, Lee H, Sun JM, Ahn JS, Ahn MJ, Park K. Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 30205417 DOI: 10.4143/crt.2018.366  0.8
2018 Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, ... ... Park K, et al. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 30177585 DOI: 10.4143/crt.2018.324  0.8
2018 Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, Sun JM, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 30049203 DOI: 10.4143/crt.2018.151  0.8
2018 Lee J, Jung HA, Kim Y, Choi S, Han J, Choi YL, Lee SH, Ahn JS, Park K, Sun JM. Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. Lung Cancer (Amsterdam, Netherlands). 122: 160-164. PMID 30032825 DOI: 10.1016/j.lungcan.2018.06.009  0.8
2018 Kang BM, Baek JH, Park SJ, Baek SK, Park KJ, Choi HJ, Bae BN, Choi SK, Kim KT, Kim JS, Lee SH. Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study. Annals of Coloproctology. 34: 144-151. PMID 29991203 DOI: 10.3393/ac.2017.09.26.1  0.44
2018 Kim MJ, Kim SM, Jung HA, Hong JY, Chang WJ, Choi MK, Kim HS, Sun JM, Park K, Ahn MJ. Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The Korean Journal of Internal Medicine. PMID 29914230 DOI: 10.3904/kjim.2017.234  0.8
2018 Lee H, Lee HY, Sun JM, Lee SH, Kim Y, Park SE, Ahn JS, Park K, Ahn MJ. Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29775809 DOI: 10.1016/j.jtho.2018.04.038  0.8
2018 Park BJ, Cho JH, Lee JH, Shin S, Kim HK, Choi YS, Zo JI, Shim YM, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K, Kim J. Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. Lung Cancer (Amsterdam, Netherlands). 117: 7-13. PMID 29496256 DOI: 10.1016/j.lungcan.2018.01.004  0.8
2018 Cho JH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 13: e34-e36. PMID 29472055 DOI: 10.1016/j.jtho.2017.10.007  0.8
2018 Sun JM, Lee KH, Kim BS, Kim HG, Min YJ, Yi SY, Yun HJ, Jung SH, Lee SH, Ahn JS, Park K, Ahn MJ. Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). British Journal of Cancer. PMID 29381690 DOI: 10.1038/bjc.2017.465  0.8
2018 Lee J, Kim HK, Park BJ, Cho JH, Choi YS, Zo JI, Shim YM, Pyo H, Ahn YC, Ahn JS, Ahn MJ, Park K, Kim J. Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer. Lung Cancer (Amsterdam, Netherlands). 115: 89-96. PMID 29290268 DOI: 10.1016/j.lungcan.2017.11.020  0.44
2017 Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H, Jeon MJ, Kim TY, Kim SW, Kim WB, Kim SW, Lee DH, Park K, Ahn MJ, Chung JH, et al. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology. 7: e1375642. PMID 29296533 DOI: 10.1080/2162402X.2017.1375642  0.44
2017 Park KH, Gu DR, Jin SH, Yoon CS, Ko W, Kim YC, Lee SH. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling. The American Journal of Chinese Medicine. 1-20. PMID 29121799 DOI: 10.1142/S0192415X17500938  0.44
2017 Cho JH, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. KIF5B-MET gene rearrangement with robust anti-tumor activity in response to crizotinib in lung adenocarcinoma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29102694 DOI: 10.1016/j.jtho.2017.10.014  0.8
2017 Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29101058 DOI: 10.1016/j.jtho.2017.10.011  0.8
2017 Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. Oncotarget. 8: 67526-67537. PMID 28978051 DOI: 10.18632/oncotarget.18728  0.8
2017 Sun JM, Noh JM, Oh D, Kim HK, Lee SH, Choi YS, Pyo H, Ahn JS, Jung SH, Chan Ahn Y, Kim J, Ahn MJ, Zo JI, Shim YM, Park K. Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28962948 DOI: 10.1016/j.jtho.2017.09.1954  0.8
2017 Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. Expert Review of Molecular Diagnostics. PMID 28838271 DOI: 10.1080/14737159.2017.1372196  0.8
2017 Lee Y, Balikov DA, Lee JB, Lee SH, Lee SH, Lee JH, Park KD, Sung HJ. In Situ Forming Gelatin Hydrogels-Directed Angiogenic Differentiation and Activity of Patient-Derived Human Mesenchymal Stem Cells. International Journal of Molecular Sciences. 18. PMID 28777301 DOI: 10.3390/ijms18081705  0.44
2017 Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. Oncotarget. PMID 28706130 DOI: 10.18632/oncotarget.18728  0.8
2017 Jeon SB, Ryoo SM, Lee DH, Kwon SU, Jang S, Lee EJ, Lee SH, Han JH, Yoon MJ, Jeong S, Cho YU, Jo S, Lim SB, Kim JG, Lee HB, ... ... Park KW, et al. Multidisciplinary Approach to Decrease In-Hospital Delay for Stroke Thrombolysis. Journal of Stroke. 19: 196-204. PMID 28592785 DOI: 10.5853/jos.2016.01802  0.44
2017 Choi YW, Kim YG, Song MY, Moon JY, Jeong KH, Lee TW, Ihm CG, Park KS, Lee SH. Potential urine proteomics biomarkers for primary nephrotic syndrome. Clinical Proteomics. 14: 18. PMID 28522940 DOI: 10.1186/s12014-017-9153-1  0.44
2017 Cho M, Ahn S, Hong M, Bang H, Van Vrancken M, Kim S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Sun JM, Lee SH, Ahn MJ, ... Park K, et al. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. Oncotarget. PMID 28477007 DOI: 10.18632/oncotarget.17199  0.8
2017 Im YJ, Lee JK, Lee SH, Oh SJ, Park K. Developmental Changes of Contractile Responses to Cholinergic Stimuli: Role of Calcium Sensitization and Related Pathways. American Journal of Physiology. Renal Physiology. ajprenal.00597.2016. PMID 28446461 DOI: 10.1152/ajprenal.00597.2016  0.44
2017 Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K. Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea. Asia-Pacific Journal of Clinical Oncology. PMID 28419723 DOI: 10.1111/ajco.12645  0.44
2017 Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opinion On Drug Safety. 1-5. PMID 28271729 DOI: 10.1080/14740338.2017.1300656  0.8
2017 Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Osimertinib for the Treatment of Non-small Cell Lung Cancer. Expert Opinion On Pharmacotherapy. PMID 28116908 DOI: 10.1080/14656566.2017.1285283  0.8
2017 Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin In East Asian Patients with Stage IV Squamous Non-Small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 28111429 DOI: 10.4143/crt.2016.423  0.44
2017 Kim Y, Lee SJ, Lee JY, Lee SH, Sun JM, Park K, An HJ, Cho JY, Kang EJ, Lee HY, Kim J, Keam B, Kim HR, Lee KE, Choi MY, et al. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer. PMID 28102887 DOI: 10.1002/cncr.30537  0.8
2017 Sun JM, Park K. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer? Current Opinion in Oncology. PMID 28085680 DOI: 10.1097/CCO.0000000000000350  0.8
2016 Cha YK, Lee HY, Ahn MJ, Park K, Ahn JS, Sun JM, Choi YL, Lee KS. The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Journal of Thoracic Disease. 8: 3175-3186. PMID 28066597 DOI: 10.21037/jtd.2016.11.25  0.8
2016 Park H, Oh D, Ahn YC, Pyo H, Noh JM, Sun JM, Ahn JS, Ahn MJ, Park K, Kim HK, Choi YS, Kim J, Zo JI, Shim YM. Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-Small Cell Lung Cancer: Elucidation Based on Single Institute Experience. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 28052657 DOI: 10.4143/crt.2016.442  0.8
2016 Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Park K, Oh YL, Hong M, Jeong HS, Son YI, Baek CH, Ahn MJ. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 28052655 DOI: 10.4143/crt.2016.424  0.8
2016 Kim ST, Kim SY, Klempner SJ, Yoon J, Kim N, Ahn S, Bang H, Kim KM, Park W, Park SH, Park JO, Park YS, Lim HY, Lee SH, Park K, et al. Rapamycin-insensitive companion of mTOR (RICTOR) Amplification Defines a Subset of Advanced Gastric Cancer and is Sensitive to AZD2014-mediated mTORC1/2 Inhibition. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28028034 DOI: 10.1093/annonc/mdw669  0.44
2016 Lim SH, Kim SY, Kim K, Jang H, Ahn S, Kim KM, Kim NK, Park W, Lee SJ, Kim ST, Park SH, Park JO, Park YS, Lee SH, Lim HY, ... Park K, et al. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. Oncotarget. PMID 27906677 DOI: 10.18632/oncotarget.13700  0.44
2016 Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K. Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: 2051-2052. PMID 27866634 DOI: 10.1016/j.jtho.2016.09.130  0.8
2016 Lim SH, Shim YM, Park SH, Kim HK, Choi YS, Ahn MJ, Park K, Zo JI, Sun JM. A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or Without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 27857024 DOI: 10.4143/crt.2016.417  0.8
2016 Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K. Vandetanib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring RET Rearrangement: A Phase II Clinical Trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27803005 DOI: 10.1093/annonc/mdw559  0.8
2016 Cho WK, Oh D, Ahn YC, Shim YM, Zo JI, Sun JM, Ahn MJ, Park K. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. Oncotarget. PMID 27682879 DOI: 10.18632/oncotarget.12200  0.8
2016 Moon SH, Kim HS, Cho YS, Sun JM, Ahn JS, Park K, Kim BT, Ahn MJ, Lee KH. Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. Lung Cancer (Amsterdam, Netherlands). 100: 24-9. PMID 27597277 DOI: 10.1016/j.lungcan.2016.07.025  0.8
2016 Choi JW, Kong DS, Seol HJ, Nam DH, Yoo KH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee JI. Outcomes of gamma knife radiosurgery in combination with crizotinib for patients with brain metastasis from non-small cell lung cancer. World Neurosurgery. PMID 27565474 DOI: 10.1016/j.wneu.2016.08.046  0.8
2016 Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Medical Oncology (Northwood, London, England). 33: 97. PMID 27447711 DOI: 10.1007/s12032-016-0811-3  0.8
2016 Kim H, Chan Ahn Y, Pyo H, Oh D, Noh JM, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM, Lee M, Han J. Do new pN sub-classifications, proposed by IASLC's lung cancer staging project, agree with ypN categories following tri-modality therapy for initial N2 disease? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27423392 DOI: 10.1016/j.jtho.2016.07.005  0.8
2016 Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, Lee SH, Ahn JS, Park K, Kim JH, Cho BC, Ahn MJ. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. Cancer. PMID 27315356 DOI: 10.1002/cncr.30135  0.8
2016 Lee JJ, Han SJ, Kim HS, Hong KS, Choi HH, Park KT, Seo JY, Lee TH, Kim HC, Kim S, Lee SH, Hwang SM, Ha SO. Out-of-hospital cardiac arrest patients treated with cardiopulmonary resuscitation using extracorporeal membrane oxygenation: focus on survival rate and neurologic outcome. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. 24: 74. PMID 27193212 DOI: 10.1186/s13049-016-0266-8  0.44
2016 Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ, Park W. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. Journal of Pathology and Translational Medicine. PMID 27160687 DOI: 10.4132/jptm.2016.04.19  0.44
2016 Kim HK, Cho JH, Choi YS, Zo JI, Shim YM, Park K, Ahn MJ, Ahn YC, Kim K, Kim J. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. Lung Cancer (Amsterdam, Netherlands). 96: 56-62. PMID 27133751 DOI: 10.1016/j.lungcan.2016.03.016  0.44
2016 Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH. Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget. PMID 27121209 DOI: 10.18632/oncotarget.8904  0.44
2016 Lee JH, Lee HY, Ahn MJ, Park K, Ahn JS, Sun JM, Lee KS. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 16: 5. PMID 26984681 DOI: 10.1186/s40644-016-0063-7  0.8
2016 Ku BM, Yi SY, Koh J, Bae YH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. PMID 26909611 DOI: 10.18632/oncotarget.7543  0.8
2016 Kim N, Cho A, Watanabe H, Choi YL, Aziz M, Kassner M, Joung JG, Park AK, Francis JM, Bae JS, Ahn SM, Kim KM, Park JO, Park WY, Ahn MJ, ... Park K, et al. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. Oncotarget. PMID 26883194 DOI: 10.18632/oncotarget.7318  0.44
2016 Kang MK, Oh D, Cho KH, Moon SH, Wu HG, Heo DS, Ahn YC, Park K, Park HJ, Park JS, Keum KC, Cha J, Kim JW, Kim YS, Kang JH, et al. ERRATUM: Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 48: 425. PMID 26809962 DOI: 10.4143/crt.2014.141.2  0.32
2016 Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion On Biological Therapy. PMID 26800463 DOI: 10.1517/14712598.2016.1145652  0.8
2016 Ham JS, Kim S, Kim HK, Byeon S, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Han J, Park W, Ahn MJ. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: e1-4. PMID 26762749 DOI: 10.1016/j.jtho.2015.09.013  0.8
2016 Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, ... Park K, et al. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget. PMID 26755650 DOI: 10.18632/oncotarget.6874  0.8
2016 Karlovich CA, Goldman J, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel DR, Soria JC, Solomon B, Camidge DR, Gadgeel SM, Paweletz CP, ... ... Park K, et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26747242 DOI: 10.1158/1078-0432.CCR-15-1260  0.8
2015 Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, Kim HS, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Park W, Ahn MJ. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26749488 DOI: 10.1016/j.jtho.2015.12.093  0.8
2015 Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26725183 DOI: 10.1016/j.jtho.2015.11.008  0.44
2015 Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, Button P, Ahn MJ, Mok T. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. Jama Oncology. 1-8. PMID 26720423 DOI: 10.1001/jamaoncol.2015.4921  0.44
2015 Lee JY, Sun JM, Oh DR, Lim SH, Goo J, Lee SH, Kim SB, Park KU, Kim HK, Hong DS, Kim JS, Kim SG, Yi SY, Yun HJ, Hyun MS, ... ... Park K, et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 26705681 DOI: 10.1016/j.radonc.2015.11.030  0.8
2015 Lee JY, Sun JM, Lim SH, Kim H, Yoo KH, Jung KS, Song HN, Ku BM, Koh J, Bae YH, Lee SH, Ahn JS, Park K, Ahn MJ. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26667485 DOI: 10.1158/1078-0432.CCR-15-1653  0.8
2015 Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, Ahn YC, Jung SH, Ahn MJ, Park K, Zo JI, Shim YM, Sun JM. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. European Journal of Cancer (Oxford, England : 1990). 52: 1-9. PMID 26623522 DOI: 10.1016/j.ejca.2015.09.019  0.8
2015 Lim SH, Lee SJ, Ahn MJ, Park K, Sun JM. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. Japanese Journal of Clinical Oncology. PMID 26561556 DOI: 10.1093/jjco/hyv163  0.8
2015 Yoo CE, Moon HS, Kim YJ, Park JM, Park D, Han KY, Park K, Sun JM, Park WY. Highly dense, optically inactive silica microbeads for the isolation and identification of circulating tumor cells. Biomaterials. 75: 271-278. PMID 26513419 DOI: 10.1016/j.biomaterials.2015.10.033  0.8
2015 Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH, Baek CH, Son YI, Jeong HS, Ahn YC, Lee MY, Hong M, Ahn MJ. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 26511814 DOI: 10.4143/crt.2015.249  0.8
2015 Kang JH, Ahn MJ, Kim DW, Cho EK, Kim JH, Shin SW, Wang X, Kim JS, Orlando M, Park K. Tolerability and Outcomes of First-line Pemetrexed+Cisplatin Followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 26511807 DOI: 10.4143/crt.2015.135  0.44
2015 Park S, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ. Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget. PMID 26439803 DOI: 10.18632/oncotarget.5131  0.8
2015 Cho KR, Lee MH, Kong DS, Seol HJ, Nam DH, Sun JM, Ahn JS, Ahn MJ, Park K, Kim ST, Lim DH, Lee JI. Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. Journal of Neuro-Oncology. PMID 26373297 DOI: 10.1007/s11060-015-1915-x  0.8
2015 Lee SJ, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. Lung Cancer (Amsterdam, Netherlands). PMID 26371700 DOI: 10.1016/j.lungcan.2015.08.020  0.8
2015 Ji JH, Oh YL, Hong M, Yun JW, Lee HW, Kim D, Ji Y, Kim DH, Park WY, Shin HT, Kim KM, Ahn MJ, Park K, Sun JM. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. Plos Genetics. 11: e1005467. PMID 26295973 DOI: 10.1371/journal.pgen.1005467  0.8
2015 Yoshioka H, Azuma K, Yamamoto N, Takahashi T, Nishio M, Katakami N, Ahn MJ, Hirashima T, Maemondo M, Kim SW, Kurosaki M, Akinaga S, Park K, Tsai CM, Tamura T, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV non-squamous non-small-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26153496 DOI: 10.1093/annonc/mdv288  0.44
2015 Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, Ahn MJ, Park K, Kim BT. Prognostic value of volume-based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Clinical and Experimental Otorhinolaryngology. 8: 142-8. PMID 26045913 DOI: 10.3342/ceo.2015.8.2.142  0.44
2015 Hwang IG, Kang JH, Oh SY, Lee S, Kim SH, Song KH, Son C, Park MJ, Kang MH, Kim HG, Lee J, Park YS, Sun JM, Kim HJ, Kim CK, ... ... Park K, et al. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 26041481 DOI: 10.1007/s00520-015-2783-9  0.8
2015 Woo HI, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ. Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients. Pharmacogenomics. 16: 383-91. PMID 25823786 DOI: 10.2217/pgs.15.14  0.8
2015 Noh JM, Ahn YC, Lee H, Pyo H, Kim B, Oh D, Park H, Lee E, Park K, Ahn JS, Ahn MJ, Sun JM. Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 25687864 DOI: 10.4143/crt.2014.144  0.8
2015 Kang MK, Oh D, Cho KH, Moon SH, Wu HG, Heo DS, Ahn YC, Park K, Park HJ, Park JS, Keum KC, Cha J, Kim JW, Kim YS, Kang JH, et al. Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 25687858 DOI: 10.4143/crt.2014.141  0.32
2015 Lim SH, Lee JY, Lee MY, Kim HS, Lee J, Sun JM, Ahn JS, Um SW, Kim H, Kim BS, Kim ST, Na DL, Sun JY, Jung SH, Park K, et al. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 762-8. PMID 25538174 DOI: 10.1093/annonc/mdu584  0.8
2015 Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH, Park K, Lee KS. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clinical Lung Cancer. 16: 228-36. PMID 25499173 DOI: 10.1016/j.cllc.2014.11.002  0.44
2015 Baek JH, Sun JM, Min YJ, Cho EK, Cho BC, Kim JH, Ahn MJ, Park K. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Lung Cancer (Amsterdam, Netherlands). 87: 148-54. PMID 25498243 DOI: 10.1016/j.lungcan.2014.11.013  0.8
2015 Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, et al. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma Oncotarget. 6: 44971-44984. DOI: 10.18632/oncotarget.6056  0.8
2015 Kim ST, Lee J, Hong M, Park K, Park JO, Ahn TJ, Park SH, Park YS, Lim HY, Sun JM, Ahn JS, Ahn MJ, Kim HC, Sohn TS, Choi DI, et al. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: Prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Oncotarget. 6: 33358-33368. DOI: 10.18632/oncotarget.5188  0.8
2014 Lee M, Jung KS, Kim HS, Lee JY, Lim SH, Kim M, Jung HA, Kim SM, Lee J, Lim DH, Park KW, Yi SY, Hwang IG, Lee S, Ahn HK, et al. 680PPHASE II STUDY OF A COMBINATION CHEMOTHERAPY WITH WEEKLY DOCETAXEL AND GEMCITABINE IN PREVIOUSLY TREATED METASTATIC ESOPHAGEAL SQUAMOUS CELL CANCER. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv231. PMID 28171149 DOI: 10.1093/annonc/mdu334.65  0.32
2014 Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, Ahn MJ, Park K, Kim BT. Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 14: 2. PMID 25609313 DOI: 10.1186/1470-7330-14-2  0.44
2014 Park K, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1523-31. PMID 25521398 DOI: 10.1097/JTO.0000000000000275  0.44
2014 Ku BM, Jung HA, Sun JM, Ko YH, Jeong HS, Son YI, Baek CH, Park K, Ahn MJ. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. Journal of Translational Medicine. 12: 299. PMID 25343854 DOI: 10.1186/s12967-014-0299-6  0.8
2014 Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. The Lancet. Oncology. 15: 1254-62. PMID 25232001 DOI: 10.1016/S1470-2045(14)70402-4  0.8
2014 Park K, Sun JM. Letter to the editor on 'Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small cell lung cancer'. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 1866. PMID 25028705 DOI: 10.1093/annonc/mdu244  0.8
2014 Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer (Oxford, England : 1990). 50: 2219-30. PMID 24953333 DOI: 10.1016/j.ejca.2014.05.011  0.44
2014 Ahn MJ, Kim SW, Cho BC, Ahn JS, Lee DH, Sun JM, Massey D, Kim M, Shi Y, Park K. Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR. The Oncologist. 19: 702-3. PMID 24868099 DOI: 10.1634/theoncologist.2013-0419  0.8
2014 Lee H, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. Annals of Surgical Oncology. 21: 2083-90. PMID 24522994 DOI: 10.1245/s10434-014-3540-x  0.8
2014 Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. Lung Cancer (Amsterdam, Netherlands). 84: 51-5. PMID 24521819 DOI: 10.1016/j.lungcan.2014.01.017  0.8
2014 Sun JM, Lira M, Pandya K, Choi YL, Ahn JS, Mao M, Han J, Park K, Ahn MJ, Kim J. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 83: 259-64. PMID 24300132 DOI: 10.1016/j.lungcan.2013.11.009  0.8
2013 Lee JY, Lim SH, Lee JY, Kim JH, Choi KH, Park K, Sun JM, Ahn JS, Ahn MJ. Tumor lysis syndrome in a solid tumor: a case report of a patient with invasive thymoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 45: 343-8. PMID 24454007 DOI: 10.4143/crt.2013.45.4.343  0.8
2012 Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: e36-8. PMID 23154564 DOI: 10.1097/JTO.0b013e318274694e  0.8
2012 Kim YN, Lee HY, Lee KS, Seo JB, Chung MJ, Ahn MJ, Park K, Kim TS, Yi CA. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response? Korean Journal of Radiology. 13: 702-10. PMID 23118568 DOI: 10.3348/kjr.2012.13.6.702  0.44
2012 Bae SH, Ahn YC, Nam H, Park HC, Pyo HR, Shim YM, Kim J, Kim K, Ahn JS, Ahn MJ, Park K. High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer. Yonsei Medical Journal. 53: 1120-7. PMID 23074111 DOI: 10.3349/ymj.2012.53.6.1120  0.44
2011 Sun J, Ahn JS, Park K, Han JH, Ahn M. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7579. PMID 28023130 DOI: 10.1200/jco.2011.29.15_suppl.7579  0.44
2011 Tan E, Park K, Lim WT, Ahn M, Ng QS, Ahn JS, Tan DS, Sun J, Jac J, Han M, Payumo FC, Credi M, McKee K, Cotreau MM, Bhargava P, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7571. PMID 28023115 DOI: 10.1200/jco.2011.29.15_suppl.7571  0.44
2011 Ahn HK, Choi YL, Sun J, Ahn YC, Kim K, Kim J, Shim YM, Ahn JS, Park K, Ahn M. The association of epidermal growth factor receptor (EGFR) mutation and survival in N2(+) non-small cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7034. PMID 28020054 DOI: 10.1200/jco.2011.29.15_suppl.7034  0.44
2011 Lee S, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, Park YH, Ahn JS, Park K, Han JH, Ahn MJ. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. Journal of Cancer Research and Clinical Oncology. 137: 1203-11. PMID 21626008 DOI: 10.1007/s00432-011-0986-0  0.8
2006 Lim do H, Lee J, Lee HG, Park BB, Peck KR, Oh WS, Ji SH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, ... Park K, et al. Pulmonary complications after hematopoietic stem cell transplantation. Journal of Korean Medical Science. 21: 406-11. PMID 16778380 DOI: 10.3346/jkms.2006.21.3.406  0.44
2004 Ji SH, Lee SH, Kim JH, Kim K, Kim WS, Park JO, Jung CW, Kang WK, Lee MH, Park K. Dose-intensive CHOP chemotherapy followed by radiation for localized NK/T-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6716. PMID 28014693 DOI: 10.1200/jco.2004.22.14_suppl.6716  0.44
2004 Lee SH, Lee JY, Im YH, Park J, Kim HY, Park YS, Kim JH, Nam SJ, Yang JH, Park K. Doxorubicin plus docetaxel as neoadjuvant treatment in patients with large (T>5cm), locally advanced carcinoma of the breast. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 746. PMID 28013627 DOI: 10.1200/jco.2004.22.14_suppl.746  0.44
2004 Lee SH, Kang WK, Park J, Kim HY, Kim JH, Lee SI, Park JO, Kim K, Jung CW, Park YS, Im YH, Lee MH, Park K. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer British Journal of Cancer. 91: 18-22. PMID 15188010 DOI: 10.1038/sj.bjc.6601891  0.44
2004 Park SH, Lee MH, Lee SH, Lee KE, Park J, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K, Kim SW, Lee KH, Lee JH. The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation Journal of Korean Medical Science. 19: 79-82. PMID 14966346 DOI: 10.3346/jkms.2004.19.1.79  0.44
Show low-probability matches.